Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Generative AI is infiltrating everything you do online, including how you find information. If you're bored with traditional search, check out the top AI search engines we've tried. I’ve been writing ...

Are you worried about online privacy? Not a fan of anticompetitive practices? Maybe you just want a new take on web search? These 12 search engines beat Google in many ways. I've been testing PC and ...

The past year was a particularly transformative year for search, witnessing significant advancements in search engine algorithms, artificial intelligence integration, and user experience enhancements.

Are you worried about online privacy? Not a fan of anticompetitive practices? Maybe you just want a new take on web search? These 12 search engines beat Google in many ways. Our team tests, rates, and ...

Steve Nix is a member of the Society of American Foresters and a former forest resources analyst for the state of Alabama. According to National Wildlife Federation, there are two varieties of Douglas ...